Flt3L, DCs, and NTregs: team contra GVHD? by Manz, M G
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
Flt3L, DCs, and NTregs: team contra GVHD?
Manz, M G
Manz, M G (2009). Flt3L, DCs, and NTregs: team contra GVHD? Blood, 113(25):6267-6268.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Blood 2009, 113(25):6267-6268.
Manz, M G (2009). Flt3L, DCs, and NTregs: team contra GVHD? Blood, 113(25):6267-6268.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Blood 2009, 113(25):6267-6268.
● ● ● IMMUNOBIOLOGY
Comment on Swee et al, page 6277
Flt3L, DCs, and NTregs: team contra
GVHD?
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Markus G. Manz INSTITUTE FOR RESEARCH IN BIOMEDICINE
In this issue, Swee and colleagues show that supraphysiologic levels ofFlt3L indirectly
lead toproliferation of peripheral naturally occurringCD4Tregulatory cells, and
correlate these findings to prevention of death in a graft-versus-host diseasemodel.
Dendritic cells (DCs) are a numericallysmall population of cells that control
T-cell responses via efficient antigen presenta-
tion onmajor histocompatibility complexmol-
ecules in combination with finely tuned co-
stimulatory signals.1 Fms-like tyrosine kinase
3 ligand (Flt3L) is a nonredundant cytokine
required forDC homeostasis in lymphoid
tissues, with its absence leading to reduction
and supraphysiologic levels leading tomassive
expansion of DCs.2 Flt3, the receptor for
Flt3L, is broadly expressed on hematopoietic
progenitor cells. However, the only differenti-
ated hematopoietic cells expressing detectable
levels of Flt3 in steady state areDCs.3
Naturally occurring CD4 regulatory
T cells (NTregs) are critical for suppression of
autoimmunity, and the control of potentially
harmful immune responses induced by non-
self antigens via thus far not fully understood
mechanisms. NTregs are generated from thy-
mocytes carryingT-cell receptors (TCRs)
with high affinity for self-peptidemajor histo-
compatibility class II (MHCII) complexes,
express high levels of the IL-2 receptor, and
specifically express the regulatory T cells
(Tregs) master-regulator transcription factor
FoxP3 (CD4CD25FoxP3NTreg).4
NTregs, together with a smaller fraction of
Tregs generated in the periphery fromCD4
T cells, account for about 10% of the total
CD4T-cell pool. They are homeostatically
maintained in steady state by someTCR-
MHCII and, perhaps more importantly,
costimulatory molecule interactions occur-
ring preferentially with DCs, by IL-2, pro-
duced mostly by nonregulatory T cells and
by TGF.4-6
In the current study, Swee et al elegantly
link Flt3L,DCs, andTreg numbers and point
to a potential clinical application of their find-
ings.7 They first demonstrate that absence of
Flt3L leads to a 2-fold reduction, while injec-
tion of Flt3L leads to a 2-fold increase of
Tregs inmice (see figure). Total CD4 cell
numbers were not significantly affected.
Flt3L-mediatedTreg expansion occurred
in the periphery, as thymic Treg numbers
were not altered and comparable Treg expan-
sion occurred in thymectomizedmice. Trans-
fer of non-Tregs and subsequent Flt3L in-
jection as well as in vivo labeling of DNA in
replicating cells revealed that Flt3L-induced
Treg expansion was achieved by a fraction of
preexistingNTregs and not by conversion of
CD4FoxP3T cells to Tregs. Since T cells
do not express functional Flt3, Flt3L-induced
NTreg expansionmust be indirect. NK cells,
which are the second (after DCs)major fold-
expanded cell population in Flt3L-injected
mice, were ruled out as contributors toNTreg
expansion, pointing toDCs as the likely criti-
cal cell population. Indeed, coculture experi-
ments confirmed that DCs, in combination
with non-DC–produced IL-2, induced prolif-
eration of a fraction of NTregs. Of note,
NTreg proliferation occurred only upon cell-
to-cell contact or close proximity of DCs and
NTregs, and was possible even in absence of
Left panel: Proportions of DCs, CD4FoxP3Treg cells, and CD4FoxP3 T cells in spleens of Flt3L-deficient
(Flt3L/), wild-type, and Flt3L-injected mice (10 g/day i.p. or s.c. over 10 days). Right panel: Factors involved
in Flt3L-mediated DC and subsequent CD4FoxP3Treg cell expansion. Flt3L expands DCs from DC
progenitors but does not act directly on CD4FoxP3Treg cells. Treg expansion is dependent on exogenous
IL-2 not produced by DCs, and on direct cell contact or close proximity to DCs. The factors provided by DCs to
Tregs need to be defined, but Treg expansion in experimental settings used by Swee et al is not dependent on
TCR-MHCII complex interaction. Professional illustration by Kenneth X. Probst.
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MHCII expression onDCs and thus, Treg-
TCR stimulation. Previous studies demon-
strated a role of DCs andTregs inmodulating
graft-versus-host disease (GVHD), with re-
cipient Flt3L pretreatment before transplan-
tation or donor Treg infusions after transplan-
tation reducing death rates fromGVHD in
differentmodel systems.8,9 Swee and colleagues
tested effects ofFlt3L injection in 2parent toF1
(C57BL6- C57BL6xDBA/2)GVHDmod-
els. Flt3Lpretreatmentwith lymphocyte only
transplantation and continuedFlt3L treatment
with sublethal irradiation followedby combined
bonemarrowand lymphocyte transplantation
led to full andpartial protection fromGVHD,
respectively.The latterwas correlatedwith
higher relative hostDCs, andhost anddonor
Tregnumbers after transplantation.
This study thus reveals a view to a so far
nonappreciated Flt3L-driven, numeric DC-
Treg cell dependency and starts to unravel the
mechanisms behind it. However, as pointed
out by the authors, the findings also raise new
questions:What are the cell-contact or close
proximity signals exchanged betweenDCs
andTregs? Are low-level “costimulatory”
signals without TCR signaling sufficient,
given appropriate Treg IL-2R stimulation? Is
restricted in vivo availability of IL-2 the limit-
ing factor for “only” 2-fold expansion of Tregs
compared with the approximately 18-fold ex-
pansion of DCs upon Flt3L administration?
Does Treg expansion in a chimericMHC-
mismatched setting in combination with irra-
diation or chemotherapy-induced lymphope-
nia follow the same rules as in the syngeneic,
that is, fullyMHC-matched setting? Is the
observed amelioration of GVHD associated
with a general state of immunosuppression,
equally limiting graft-versus-leukemia and
possibly reactions to invading pathogens? Or
could strongDC-activating agents as TLR
agonists from infectious agents turn Flt3L-
expandedDCs into strong stimulators of al-
loresponses, enhancingGVHD?And finally,
how do the data on combinedDC andNTreg
expansion correlate with the findings that se-
lective Treg ablation inmice leads to increase
DC numbers?10 Continuing research along the
lines of Swee and colleagues will likely
broaden future therapeutic options in trans-
plantation and other clinical settings requiring
immune-systemmodulation.
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NKT cells in p53 deficiency
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Madhav V. Dhodapkar and Natalia Neparidze YALE UNIVERSITY
In this issue ofBlood, Swann and colleagues show that type INKT cells mediate
protection against tumor development in p53-deficient mice.
Tumor suppressor p53 serves as a guardian ofthe genome andplays a key role in preserv-
ing genomic integrity in response to several
stressors includingDNAdamage andoncogene
activation.1Not surprisingly,malfunction of
thep53pathway is an almost universal feature
of human cancers.However,when this cell-
intrinsic control fails, the immune systemmay
provide an additional barrier to thedevelop-
ment of cancers.
Natural killerT (NKT) cells are innate lym-
phocytes that recognize glycolipid ligands in
the context ofCD1d.2At least 2 broad groups
ofNKTcells have beendescribed.Type I
NKTcells express an invariantT-cell receptor
(V24 in humans), andhave been extensively
studied in the context of response to glycolipid,
-galactosylceramide. In contrast, type IINKT
cells express diverseT-cell receptors and ligands
recognizedby these cells are just beginning to
emerge.3NKTcells have been implicated as
conductors of the immune systemand canhave
several effects, including the activation of
NK cells anddendritic cells (DCs), ultimately
leading to the activation of adaptive immunity.4
Type INKTcells canmediate antitumor effects
by severalmechanisms includingNKactivation,
direct cytotoxicity, and antiangiogenesis. In this
issue, Swann et al demonstrate a critical role for
type INKTcells in protection against diverse
tumor types in a clinically relevantmodel of p53-
deficientmice.5These findings set the stage for
studies to better understand themechanismof
tumor immune surveillance byNKTcells. It
wouldbe important to discern the overlap/
synergywith other pathways such as host
interferon-, tumornecrosis factor–related
apoptosis-inducing ligand (TRAIL), andper-
forin, also known to regulate tumorigenesis in
this setting6 (see figure). Better understanding of
the biology of tumors that escapeprotectionby
NKTcells is alsoneeded.Stressors, such asDNA
damage, that activate intrinsic defenses (such as
p53)maysensitize tumor cells for innate immune
defense.6Therefore, the 2pathwaysmayprovide
a synergistic defense against tumorigenesis.
The data in this paper suggest that the ef-
fects of type INKT cells may dominate over
those of type II NKT cells in thesemice. How-
ever, improved understanding of type II NKT
cells is needed to elucidate their role in tumor
immunity and cross-talk with type INKT
cells. It is also critical to understand the nature
of tumor-derived ligands recognized by both
type I and II NKT cells inmice and humans.
However, in contrast tomice, the propor-
tion of type INKT cells in human blood and
tissues is much lower, and theremay be addi-
tional differences inNKT subsets and biology
between the 2 species.2 Nonetheless, these
findings provide strong support for systematic
studies tomanipulate NKT cell function in
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